JMP Securities Healthcare Conference September 27-28, 2010 Palace Hotel New York, NY Presentation: September 27 at 1:30pm ET http://www.jmpsecurities.com/images/pdf/JMP_Healthcare_2010_Invitation.pdf
A live and archived webcast of the presentation will be accessible on Inovio's website at http://www.inovio.com.
BIO Investor Forum October 5-6, 2010 Palace Hotel San Francisco, CA Presentation: October 6 at 12:30pmET http://www.bio.org/investorforum/
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio’s proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio’s clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More informa20Documents/www.inovio.com">www.inovio.com.
